Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001031500 | SCV001194806 | pathogenic | Progressive myoclonic epilepsy | 2019-09-09 | criteria provided, single submitter | clinical testing | This variant is a gross deletion of the genomic region encompassing exons 3-4 of the EPM2A gene. The 5' boundary is likely confined to intron 2. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. This variant has been observed in combination with another EPM2A variant in an individual suspected of having Lafora disease (PMID: 20738377). Sub-genic deletion of exon 3 has been determined to be pathogenic (PMID: 18311786). Therefore, deletions that fully encompass that region are also expected to be pathogenic. For these reasons, this variant has been classified as Pathogenic. |